Biogen Inc Cmn (BIIB) 313.59 $BIIB
Shares of BIIB Up 27.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Sep 02, 1:38PM CDT
SmarTrend identified an Uptrend for Biogen Idec (NASDAQ:BIIB) on July 7th, 2016 at $247.44. In approximately 2 months, Biogen Idec has returned 26.96% as of today's recent price of $314.14.
BIIB: 313.59 (+7.56)
Watch for Biogen Idec to Potentially Pullback After Gaining 2.54% Yesterday
Comtex SmarTrend(R) - Fri Sep 02, 12:00PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $308.66 to a high of $318.88. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $309.25 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 313.59 (+7.56)
Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 2.54% Rise
Comtex SmarTrend(R) - Fri Sep 02, 11:59AM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $308.66 to a high of $318.88. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $309.25 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 313.59 (+7.56)
Biogen (BIIB) Aducanumab Gets Fast Track Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:33AM CDT
Biogen (BIIB) granted Fast Track designation in the U.S. for aducanumab for the treatment of early stage Alzheimer's disease.
BIIB: 313.59 (+7.56), AZN: 33.31 (+0.71), LLY: 76.85 (-0.38), ANIK: 47.89 (-0.05)
Biogen to Present at the Morgan Stanley Global Healthcare Conference
BusinessWire - Thu Sep 01, 3:01PM CDT
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Morgan Stanley Global Healthcare Conference. The webcast will be live on Monday, September 12, 2016 at 1:40p.m. ET. To access the live webcast, please visit Biogen's Investors section at www.biogen.com/investors. An archived version of the webcast will be available for 14 days following the presentation.
BIIB: 313.59 (+7.56)
Biogen's Investigational Alzheimer's Disease Treatment Aducanumab Granted FDA Fast Track Designation
BusinessWire - Thu Sep 01, 3:01PM CDT
Today Biogen (NASDAQ: BIIB) announced that aducanumab, its investigational treatment for early Alzheimer's disease (AD), was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). The FDA's Fast Track program supports the development of new treatments for serious conditions with an unmet medical need such as Alzheimer's disease.
BIIB: 313.59 (+7.56)
Nature Publishes Results from Pre-Clinical Research and Phase 1b Study of Biogen's Investigational Alzheimer's Disease Treatment Aducanumab
BusinessWire - Wed Aug 31, 12:13PM CDT
--Phase 1b Exploratory Results Also Showed Dose-Dependent Slowing of Clinical Decline
BIIB: 313.59 (+7.56)
Biogen Idec Up 24.0% Since SmarTrend Uptrend Call (BIIB)
Comtex SmarTrend(R) - Fri Aug 26, 12:54AM CDT
SmarTrend identified an Uptrend for Biogen Idec (NASDAQ:BIIB) on July 7th, 2016 at $247.44. In approximately 2 months, Biogen Idec has returned 24.01% as of today's recent price of $306.85.
BIIB: 313.59 (+7.56)
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 1:09PM CDT
Acquisitions are back in focus in the biotech sector with Medivation (MDVN) agreeing to be acquired by Pfizer for $14 billion.
MDVN: 80.85 (-0.08), BIIB: 313.59 (+7.56), PTLA: 21.03 (+0.17), CLVS: 23.40 (-0.19), GILD: 76.89 (-0.53), ALXN: 123.67 (-1.96), REGN: 388.64 (-4.76)
After Yesterday's Rally of 1.20% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Aug 19, 12:21PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $312.39 to a high of $319.89. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $316.67 on volume of 615,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 313.59 (+7.56)
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 1.20% Gain
Comtex SmarTrend(R) - Fri Aug 19, 12:20PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $312.39 to a high of $319.89. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $316.67 on volume of 615,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 313.59 (+7.56)
Biotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data
Arpita Dutt - Zacks Investment Research - Wed Aug 17, 2:49PM CDT
With second quarter earnings season drawing to a close, focus in back on pipeline and regulatory updates.
BIIB: 313.59 (+7.56), VRTX: 95.11 (+0.36), AUPH: 2.05 (+0.10), OGXI: 0.53 (-0.02), GILD: 76.89 (-0.53), AVEO: 0.90 (-0.01), AMGN: 169.77 (-0.36)
Top 3 Research Reports for August 15, 2016
Sheraz Mian - Zacks Investment Research - Mon Aug 15, 1:44PM CDT
Top 3 Research Reports for August 15, 2016
BIIB: 313.59 (+7.56), EXC: 34.07 (+0.26), AZN: 33.31 (+0.71), APA: 51.29 (+1.50), CAT: 81.69 (+0.24)
Post Earnings Coverage as Perrigo Doubles Profit
ACCESSWIRE - Mon Aug 15, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 15, 2016 / Active Wall St. announces its post-earnings coverage on Perrigo Company PLC (NYSE: PRGO). The company announced its second quarter fiscal 2016 results on August 10, 2016. The over-the-counter drug specialist doubled its profit. However, the company slashed its full-year earnings forecast for the second time in 2016, citing pricing pressure in its generic drugs business. Register with us now for your free membership at: http://www.activewallst.com/register/.
BIIB: 313.59 (+7.56), VRX: 28.76 (-0.36), PRGO: 90.75 (-0.50), MYL: 39.97 (-1.95), VRX.TO: 37.34 (-0.75)
Allergan to Buy ForSight VISION5, Boost Glaucoma Pipeline
Arpita Dutt - Zacks Investment Research - Mon Aug 15, 8:13AM CDT
The deal will see Allergan (AGN) making an upfront payment of $95 million as well as a launch milestone payment related to ForSight's lead development program.
AGN: 235.96 (-1.80), BIIB: 313.59 (+7.56), TEVA: 51.22 (+0.32), NVS: 79.38 (+1.11)
The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 8:30AM CDT
The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
BIIB: 313.59 (+7.56), BMRN: 95.73 (+0.54), AMGN: 169.77 (-0.36), ABBV: 64.12 (+0.09), REGN: 388.64 (-4.76)
Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat
Arpita Dutt - Zacks Investment Research - Thu Aug 11, 4:30PM CDT
Earnings remained in focus with several companies including Regeneron (REGN) reporting second quarter results.
MDVN: 80.85 (-0.08), BIIB: 313.59 (+7.56), BMRN: 95.73 (+0.54), AMGN: 169.77 (-0.36), ABBV: 64.12 (+0.09), MNTA: 12.30 (+0.15), REGN: 388.64 (-4.76)
24.8% Return Seen to Date on SmarTrend Biogen Idec Call (BIIB)
Comtex SmarTrend(R) - Thu Aug 11, 12:30AM CDT
SmarTrend identified an Uptrend for Biogen Idec (NASDAQ:BIIB) on July 7th, 2016 at $247.44. In approximately 1 month, Biogen Idec has returned 24.83% as of today's recent price of $308.87.
BIIB: 313.59 (+7.56)
Ionis (IONS) Q2 Loss Narrower than Expected, Issues Outlook
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 2:49PM CDT
Ionis (IONS) reported a narrower-than-expected loss of 47 cents per share in the second quarter of 2016.
BIIB: 313.59 (+7.56), GERN: 2.75 (+0.02), GSK: 44.26 (+1.28), IONS: 29.46 (-0.58)
Shares of BIIB Up 27.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Sep 02, 1:38PM CDT
SmarTrend identified an Uptrend for Biogen Idec (NASDAQ:BIIB) on July 7th, 2016 at $247.44. In approximately 2 months, Biogen Idec has returned 26.96% as of today's recent price of $314.14.
BIIB: 313.59 (+7.56)
Watch for Biogen Idec to Potentially Pullback After Gaining 2.54% Yesterday
Comtex SmarTrend(R) - Fri Sep 02, 12:00PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $308.66 to a high of $318.88. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $309.25 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 313.59 (+7.56)
Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 2.54% Rise
Comtex SmarTrend(R) - Fri Sep 02, 11:59AM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $308.66 to a high of $318.88. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $309.25 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 313.59 (+7.56)
Biogen (BIIB) Aducanumab Gets Fast Track Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:33AM CDT
Biogen (BIIB) granted Fast Track designation in the U.S. for aducanumab for the treatment of early stage Alzheimer's disease.
BIIB: 313.59 (+7.56), AZN: 33.31 (+0.71), LLY: 76.85 (-0.38), ANIK: 47.89 (-0.05)
Biogen to Present at the Morgan Stanley Global Healthcare Conference
BusinessWire - Thu Sep 01, 3:01PM CDT
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Morgan Stanley Global Healthcare Conference. The webcast will be live on Monday, September 12, 2016 at 1:40p.m. ET. To access the live webcast, please visit Biogen's Investors section at www.biogen.com/investors. An archived version of the webcast will be available for 14 days following the presentation.
BIIB: 313.59 (+7.56)
Biogen's Investigational Alzheimer's Disease Treatment Aducanumab Granted FDA Fast Track Designation
BusinessWire - Thu Sep 01, 3:01PM CDT
Today Biogen (NASDAQ: BIIB) announced that aducanumab, its investigational treatment for early Alzheimer's disease (AD), was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). The FDA's Fast Track program supports the development of new treatments for serious conditions with an unmet medical need such as Alzheimer's disease.
BIIB: 313.59 (+7.56)
Nature Publishes Results from Pre-Clinical Research and Phase 1b Study of Biogen's Investigational Alzheimer's Disease Treatment Aducanumab
BusinessWire - Wed Aug 31, 12:13PM CDT
--Phase 1b Exploratory Results Also Showed Dose-Dependent Slowing of Clinical Decline
BIIB: 313.59 (+7.56)
Biogen Idec Up 24.0% Since SmarTrend Uptrend Call (BIIB)
Comtex SmarTrend(R) - Fri Aug 26, 12:54AM CDT
SmarTrend identified an Uptrend for Biogen Idec (NASDAQ:BIIB) on July 7th, 2016 at $247.44. In approximately 2 months, Biogen Idec has returned 24.01% as of today's recent price of $306.85.
BIIB: 313.59 (+7.56)
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 1:09PM CDT
Acquisitions are back in focus in the biotech sector with Medivation (MDVN) agreeing to be acquired by Pfizer for $14 billion.
MDVN: 80.85 (-0.08), BIIB: 313.59 (+7.56), PTLA: 21.03 (+0.17), CLVS: 23.40 (-0.19), GILD: 76.89 (-0.53), ALXN: 123.67 (-1.96), REGN: 388.64 (-4.76)
After Yesterday's Rally of 1.20% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Aug 19, 12:21PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $312.39 to a high of $319.89. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $316.67 on volume of 615,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 313.59 (+7.56)
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 1.20% Gain
Comtex SmarTrend(R) - Fri Aug 19, 12:20PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $312.39 to a high of $319.89. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $316.67 on volume of 615,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 313.59 (+7.56)
Biotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data
Arpita Dutt - Zacks Investment Research - Wed Aug 17, 2:49PM CDT
With second quarter earnings season drawing to a close, focus in back on pipeline and regulatory updates.
BIIB: 313.59 (+7.56), VRTX: 95.11 (+0.36), AUPH: 2.05 (+0.10), OGXI: 0.53 (-0.02), GILD: 76.89 (-0.53), AVEO: 0.90 (-0.01), AMGN: 169.77 (-0.36)
Top 3 Research Reports for August 15, 2016
Sheraz Mian - Zacks Investment Research - Mon Aug 15, 1:44PM CDT
Top 3 Research Reports for August 15, 2016
BIIB: 313.59 (+7.56), EXC: 34.07 (+0.26), AZN: 33.31 (+0.71), APA: 51.29 (+1.50), CAT: 81.69 (+0.24)
Post Earnings Coverage as Perrigo Doubles Profit
ACCESSWIRE - Mon Aug 15, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 15, 2016 / Active Wall St. announces its post-earnings coverage on Perrigo Company PLC (NYSE: PRGO). The company announced its second quarter fiscal 2016 results on August 10, 2016. The over-the-counter drug specialist doubled its profit. However, the company slashed its full-year earnings forecast for the second time in 2016, citing pricing pressure in its generic drugs business. Register with us now for your free membership at: http://www.activewallst.com/register/.
BIIB: 313.59 (+7.56), VRX: 28.76 (-0.36), PRGO: 90.75 (-0.50), MYL: 39.97 (-1.95), VRX.TO: 37.34 (-0.75)
Allergan to Buy ForSight VISION5, Boost Glaucoma Pipeline
Arpita Dutt - Zacks Investment Research - Mon Aug 15, 8:13AM CDT
The deal will see Allergan (AGN) making an upfront payment of $95 million as well as a launch milestone payment related to ForSight's lead development program.
AGN: 235.96 (-1.80), BIIB: 313.59 (+7.56), TEVA: 51.22 (+0.32), NVS: 79.38 (+1.11)
The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 8:30AM CDT
The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
BIIB: 313.59 (+7.56), BMRN: 95.73 (+0.54), AMGN: 169.77 (-0.36), ABBV: 64.12 (+0.09), REGN: 388.64 (-4.76)
Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat
Arpita Dutt - Zacks Investment Research - Thu Aug 11, 4:30PM CDT
Earnings remained in focus with several companies including Regeneron (REGN) reporting second quarter results.
MDVN: 80.85 (-0.08), BIIB: 313.59 (+7.56), BMRN: 95.73 (+0.54), AMGN: 169.77 (-0.36), ABBV: 64.12 (+0.09), MNTA: 12.30 (+0.15), REGN: 388.64 (-4.76)
24.8% Return Seen to Date on SmarTrend Biogen Idec Call (BIIB)
Comtex SmarTrend(R) - Thu Aug 11, 12:30AM CDT
SmarTrend identified an Uptrend for Biogen Idec (NASDAQ:BIIB) on July 7th, 2016 at $247.44. In approximately 1 month, Biogen Idec has returned 24.83% as of today's recent price of $308.87.
BIIB: 313.59 (+7.56)
Ionis (IONS) Q2 Loss Narrower than Expected, Issues Outlook
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 2:49PM CDT
Ionis (IONS) reported a narrower-than-expected loss of 47 cents per share in the second quarter of 2016.
BIIB: 313.59 (+7.56), GERN: 2.75 (+0.02), GSK: 44.26 (+1.28), IONS: 29.46 (-0.58)
